📰 **Rossari Biotech Q1 FY26 Results: Modest Growth Despite Margin Pressure**

**Mumbai, July 19, 2025:** Specialty chemicals player **Rossari Biotech Limited** reported a steady performance in Q1 FY26, supported by robust demand across its core segments despite some operational headwinds. ### 🔹 **Consolidated Performance (YoY Q1 FY26 vs. Q1 FY25):** * **Revenue:** ₹543.7 crore, up **11%** YoY * **EBITDA:** ₹67.9 crore, up **4.6%** YoY * **EBITDA Margin:** **12.5%** (vs. 13.3% YoY) * **PAT:** ₹33.6 crore, down **3.7%** YoY * **EPS (Diluted):** ₹6.1 vs. ₹6.3 ### 🔹 **Standalone Performance:** * **Revenue:** ₹365.8 crore, up **21.6%** * **EBITDA:** ₹43.9 crore, up **10.3%** * **PAT:** ₹26.2 crore, up **7.8%** * **EPS (Diluted):** ₹4.7 vs. ₹4.4 ### 🔑 **Management Commentary:** Rossari’s promoters noted continued resilience in core businesses, with strong growth in **HPPC (Home, Personal Care, and Performance Chemicals)** and **AHN (Animal Health & Nutrition)**, growing **16%** and **12%**, respectively. However, the export business remained soft sequentially but grew YoY. Capacity expansions remain on track, targeting opportunities in high-growth sectors like personal care, agrochemicals, oil & gas, and pharma. ### 📊 **Outlook:** Management reaffirmed confidence in sustained execution, innovation, and long-term growth despite near-term challenges, backed by a strong balance sheet and ongoing investments.